Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Mirabegron (25mg) + Silodosin (8mg) Tablet
Therapeutic Category
Urology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Sildodime M 25 tablet is a combination of a β3-adrenoceptor agonist (Mirabegron) and an alpha-1 blocker (Silodosin) used for managing overactive bladder and lower urinary tract symptoms associated with BPH.
It works by relaxing bladder and prostate smooth muscles, improving urinary flow, reducing urgency, frequency, and nocturia, and enhancing bladder control.
This tablet is widely prescribed in overactive bladder syndrome, benign prostatic hyperplasia, and urinary retention management, helping adult patients maintain better urinary comfort and daily convenience.
With strong clinical relevance in urology therapy, growing physician acceptance, and increasing demand in bladder and BPH management, this formulation strengthens institutional and outpatient therapy portfolios and supports sustained therapeutic utilization.
Some patients may experience headache, dizziness, mild gastrointestinal discomfort, increased blood pressure, or nasal congestion. Rarely, serious cardiovascular events, allergic reactions, or urinary retention may occur and should be reported to a healthcare professional immediately.
Sildodime M 25 Tablet is indicated for adult patients experiencing symptoms of overactive bladder, such as urinary urgency, increased frequency, and urge incontinence, especially when associated with benign prostatic hyperplasia. The combination of Mirabegron and Silodosin improves bladder storage, enhances urine flow, and provides comprehensive relief from bladder and prostate-related urinary issues.
This medicine should be used under medical supervision. Patients with severe hypertension, heart disease, liver or kidney impairment, or other urological conditions should consult their healthcare provider before use. Strict adherence to the prescribed dosage is essential for safe and effective therapy.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Composition : Ursodeoxycholic Acid (150mg)
Composition : Ursodeoxycholic Acid (300mg)
Composition : Ursodeoxycholic Acid (450mg) SR
Composition : Ursodeoxycholic Acid (125mg/5ml)
Composition : Sodium Bicarbonate (500mg)
Composition : Sodium Bicarbonate (1000mg)
Composition : Obeticholic acid (5mg) Tablet
Composition : Obeticholic acid (10mg) Tablet
Composition : Rabeprazole (20mg)
Composition : Lansoprazole (30mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.